Overview

Efficacy and Safety of ALT-801 in the Treatment of Obesity

Status:
Not yet recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of ALT-801 once-weekly versus placebo as an adjunct to a reduced-calorie diet and increased physical activity in patients with obesity/overweight.
Phase:
Phase 2
Details
Lead Sponsor:
Altimmune, Inc.